Compare Novartis AG (NVS) vs Philip Morris International Inc. (PM) Price & Performance

Novartis AGTrade

Philip Morris International Inc.Trade

Price performance (Past 24H)

Key statistics

Novartis AG vs Philip Morris International Inc. — how do they compare? Novartis AG trades at $153.88 (market cap $290.25B), while Philip Morris International Inc. trades at $190.5 (market cap $300.37B). The key difference: Novartis AG and Philip Morris International Inc. are close in size by market cap, and Novartis AG pays the higher dividend (3.17%). Which is the better fit depends on your goals.

	NVS	PM
Market Cap	$290.25B	$300.37B
Sector	Health	Consumer Staples
52-Week High	$168.62	$192.98
52-Week Low	$113.50	$144.33
Enterprise Value	$330.27B	$346.86B
Dividend Yield	3.17%	3.05%

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Novartis AG

No Aura AI signal available yet.

Philip Morris International Inc.

Philip Morris International (PM) trades at $192.98, up 1.65% today, near the analyst consensus price target of $194. The stock shows a bullish technical trend with strong moving average support. Fundamentally, the company reported robust 2025 results with revenue of $40.65 billion and net income of $11.35 billion, though recent news highlights a $500 million impairment charge and reduced profit guidance for 2026 due to cost pressures.

The outlook remains cautiously optimistic with 68% of analysts rating it a Buy, but investors face headwinds from currency volatility, rising illicit tobacco trade in Europe, and margin compression. The stock's valuation at a P/E of 27.13 appears full priced, requiring continued execution to justify further upside.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

NVS

Novartis Q2 earnings expected at $2.17 EPS, $14.07B revenue amid patent loss impact and key drug trials ahead.Gordon Thompson · 1 day agoNeutral New report details 1,230+ bioinformatics deals, revealing market trends and deal structures through 2026Researchandmarkets.Com · 4 days agoNeutral FDA approves Fabhalta as first drug to significantly slow kidney decline in IgAN patientsNovartis · 4 days agoBullish View details →

BTIG starts Philip Morris International with a Buy rating, expecting strong Q2 earnings and 3.05% dividend yield.Alex Lavoie · 47 minutes agoBullish View details →

About Novartis AG

Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.

About Philip Morris International Inc.

Philip Morris International is an international tobacco company with a product portfolio primarily consisting of cigarettes and reduced-risk products, including heat-not-burn, vapor and oral nicotine products, which are sold in markets outside the United States. The company diversified away from nicotine products with the acquisition of Vectura, a provider of innovative inhaled drug delivery solutions, in 2021.